Bioscience Pharma Partners, LLC (BPP) Announces Receipt of Key Patent, Appointment of Senior Executive, Engagement of PharmaVentures Ltd. and Participation at BioEurope 2018
Bioscience Pharma Partners (“BPP”) announced that it has been granted a patent by the U.S. Patent and Trademark Office (USPTO) for the use of its 5-Lipoxygenase activating protein (FLAP) inhibitor, BPP-1001, as an oral therapeutic for neuroinflammation and neuroinflammation-mediated damage resulting from traumatic or acquired insult or injury in the CNS.
Once considered a bystander phenomenon, neuroinflammation is now broadly accepted as elemental in the progression of neurodegenerative disease. The BPP therapeutic, via both its inhibition of the biosynthesis of all four leukotrienes in the central nervous system and its associated reduction in neuronal damage, neuronal death, astrocyte cell death and cognitive deficits, targets all neuroinflammation-mediated disorders and diseases, including post-concussion syndrome (PCS), multiple sclerosis, Parkinson’s disease and Alzheimer’s disease.
Read More: The Promise and Potential of AI for the Insurance Industry
I am extremely inspired together with your writing skills and alsowell as with the layout for your blog. Is this a paid topic or did you customize it yourself? Either way stay up the nice quality writing, it’s rare to see a nice blog like this one these days..
Copper carbonate scrap acquisition Copper scrap safety standards Metal scrap dismantling
Copper cable recycling plant setup, Metal scrap sustainability, Copper recovery process